



MSI Methylation Sciences Raises \$19 Million in Series A Financing

Vancouver, British Columbia, October 4, 2011 – BC Advantage Funds (VCC) Ltd. announced today that its portfolio company, MSI Methylation Sciences (“MSI”), has raised \$19 million in a Series A Financing led by Inventages, one of the world’s largest specialized life science investment funds.

This new investment will provide MSI with sufficient funds to take its lead formulation of s-adenosyl methionine (SAME) through to the completion of a Phase II trial testing the efficacy of its formulation of SAME in the treatment of depression in humans. A long record of clinical use and a large body of credible, supporting research indicates that SAME is safe, well tolerated and clinically effective in the treatment of depression.

Gunnar Weikert, the Chairman of Inventages who has joined the Board of MSI, commented: "MSI represents a unique development company with reduced risk due to a large body of human evidence supporting safety and efficacy. MSI's products offer a safe and effective treatment alternative in depression."

Jim Heppell, President of BC Advantage Funds noted “It is encouraging to see another one of our core portfolio companies attract a significant financing from a very sophisticated source. Throughout this transaction, I have been impressed by the expertise and extensive networks of the Inventages representatives. I am stepping down from the Board of MSI comfortable that the involvement of Inventages will materially enhance the likelihood of the success of MSI.”

About Inventages

Inventages is one of the world's largest specialized life science investors with a focus on safe and efficacious therapies for chronic diseases. It invests globally in healthcare, medical nutrition and consumer health and operates out of three offices: Nassau (Bahamas), London (United Kingdom), and Geneva (Switzerland). Beyond capital infusion and board participation, Inventages strives to contribute to the growth of the management teams and companies in which they invest by leveraging its experience, together with extensive networks and relationships. For further information, please visit www.inventages.com.

About MSI Methylation Sciences

MSI Methylation Sciences Inc. was founded in 2007 and is a privately held company focused on developing new pharmaceuticals based on compounds which have human proof of concept. MSI is based in Vancouver, British Columbia Canada.

About Advantage

BC Advantage Funds (VCC) Ltd. is a venture capital corporation, formed under the Small Business Venture Capital Act (British Columbia), to invest in emerging technology companies in the Province. For more information about Advantage, please visit our website at www.bcadvantagefunds.com.

BC ADVANTAGE FUNDS (VCC) LTD.

Suite 1500 - 885 West Georgia Street

Vancouver, BC V6C 3E8

[Email: info@bcadvantagefunds.com](mailto:info@bcadvantagefunds.com)